Ryuichi Tozawa
Overview
Explore the profile of Ryuichi Tozawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
331
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Asahina M, Fujinawa R, Hirayama H, Tozawa R, Kajii Y, Suzuki T
Mol Brain
. 2021 Aug;
14(1):127.
PMID: 34399817
No abstract available.
2.
Yoshida Y, Asahina M, Murakami A, Kawawaki J, Yoshida M, Fujinawa R, et al.
Proc Natl Acad Sci U S A
. 2021 Jul;
118(27).
PMID: 34215698
Mutations in the human peptide:-glycanase gene (), which encodes a cytosolic de--glycosylating enzyme, cause a congenital autosomal recessive disorder. In rodents, the loss of results in severe developmental delay or...
3.
Asahina M, Fujinawa R, Hirayama H, Tozawa R, Kajii Y, Suzuki T
Mol Brain
. 2021 Jun;
14(1):91.
PMID: 34120625
N-glycanase 1 (NGLY1) deficiency is a rare inherited disorder characterized by developmental delay, hypolacrima or alacrima, seizure, intellectual disability, motor deficits, and other neurological symptoms. The underlying mechanisms of the...
4.
Asahina M, Fujinawa R, Fujihira H, Masahara-Negishi Y, Andou T, Tozawa R, et al.
Proc Jpn Acad Ser B Phys Biol Sci
. 2021 Feb;
97(2):89-102.
PMID: 33563880
N-Glycanase 1 (NGLY1) deficiency is a congenital disorder caused by mutations in the NGLY1 gene. Because systemic Ngly1 mice with a C57BL/6 (B6) background are embryonically lethal, studies on the...
5.
Asahina M, Fujinawa R, Nakamura S, Yokoyama K, Tozawa R, Suzuki T
Hum Mol Genet
. 2020 Apr;
29(10):1635-1647.
PMID: 32259258
N-glycanase 1 (NGLY1) deficiency, an autosomal recessive disease caused by mutations in the NGLY1 gene, is characterized by developmental delay, hypolacrima or alacrima, seizure, intellectual disability, movement disorders and other...
6.
Takada H, Kaieda A, Tawada M, Nagino T, Sasa K, Oikawa T, et al.
J Med Chem
. 2019 Sep;
62(20):9175-9187.
PMID: 31550153
Dysferlinopathies, which are muscular diseases caused by mutations in the dysferlin gene, remain serious medical problems due to the lack of therapeutic agents. Herein, we report the design, synthesis, and...
7.
Kokubu Y, Nagino T, Sasa K, Oikawa T, Miyake K, Kume A, et al.
Stem Cells Transl Med
. 2019 Jun;
8(10):1017-1029.
PMID: 31250983
Dysferlinopathy is a progressive muscle disorder that includes limb-girdle muscular dystrophy type 2B and Miyoshi myopathy (MM). It is caused by mutations in the dysferlin (DYSF) gene, whose function is...
8.
Shinozawa E, Amano Y, Yamakawa H, Haba M, Shimada M, Tozawa R
Pharmacol Res Perspect
. 2018 Mar;
6(2):e00390.
PMID: 29541476
We attempted to clarify the therapeutic capability of antagonists of the farnesoid X receptor (FXR), a nuclear receptor that regulates lipid and bile acid metabolism. Herein, we report the antidyslipidemic...
9.
Amano Y, Yamakawa H, Yonemori K, Shimada M, Tozawa R
Pharmacol Rep
. 2018 Jan;
70(1):172-177.
PMID: 29367104
Background: The effects of farnesoid X receptor (FXR) antagonists on plasma lipid profile in mice have not been investigated thus far. The aim of this study was to investigate the...
10.
Morimoto M, Amano Y, Oka M, Harada A, Fujita H, Hikichi Y, et al.
PLoS One
. 2017 Dec;
12(12):e0189480.
PMID: 29216311
Sarcopenia and cachexia present characteristic features of a decrease in skeletal muscle mass and strength, anorexia, and lack of motivation. Treatments for these diseases have not yet been established, although...